Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab consolidation or frontline therapy study in diffuse large B-cell lymphoma
2023-507498-16-00Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of mosunetuzumab and polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL) (3 cohorts), sponsored by Roche. Primary endpoints: PET-CT complete response rate or overall response rate at primary response assessment and Incidence and severity of adverse events. Started Apr 2024; status: completed.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-507498-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507498-16-00.